全文获取类型
收费全文 | 3039篇 |
免费 | 208篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 45篇 |
妇产科学 | 11篇 |
基础医学 | 656篇 |
口腔科学 | 21篇 |
临床医学 | 246篇 |
内科学 | 678篇 |
皮肤病学 | 109篇 |
神经病学 | 40篇 |
特种医学 | 36篇 |
外国民族医学 | 1篇 |
外科学 | 97篇 |
综合类 | 220篇 |
现状与发展 | 1篇 |
预防医学 | 69篇 |
眼科学 | 38篇 |
药学 | 185篇 |
2篇 | |
中国医学 | 50篇 |
肿瘤学 | 785篇 |
出版年
2024年 | 5篇 |
2023年 | 112篇 |
2022年 | 104篇 |
2021年 | 218篇 |
2020年 | 168篇 |
2019年 | 141篇 |
2018年 | 98篇 |
2017年 | 112篇 |
2016年 | 125篇 |
2015年 | 140篇 |
2014年 | 215篇 |
2013年 | 197篇 |
2012年 | 160篇 |
2011年 | 136篇 |
2010年 | 119篇 |
2009年 | 129篇 |
2008年 | 132篇 |
2007年 | 128篇 |
2006年 | 105篇 |
2005年 | 82篇 |
2004年 | 65篇 |
2003年 | 50篇 |
2002年 | 51篇 |
2001年 | 48篇 |
2000年 | 54篇 |
1999年 | 34篇 |
1998年 | 23篇 |
1997年 | 18篇 |
1996年 | 26篇 |
1995年 | 27篇 |
1994年 | 29篇 |
1993年 | 25篇 |
1992年 | 21篇 |
1991年 | 24篇 |
1990年 | 21篇 |
1989年 | 23篇 |
1988年 | 29篇 |
1987年 | 14篇 |
1986年 | 18篇 |
1985年 | 11篇 |
1984年 | 16篇 |
1983年 | 6篇 |
1982年 | 6篇 |
1981年 | 9篇 |
1980年 | 5篇 |
1979年 | 4篇 |
1977年 | 5篇 |
1976年 | 3篇 |
1974年 | 3篇 |
1970年 | 4篇 |
排序方式: 共有3303条查询结果,搜索用时 17 毫秒
1.
2.
Naveen Pemmaraju MD Jacqueline S. Garcia MD Andrew Perkins MBBS PhD Jason G. Harb PhD Andrew J. Souers PhD Michael E. Werner PhD Christopher M. Brown PhD Francesco Passamonti MD 《Cancer》2023,129(22):3535-3545
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment. 相似文献
3.
Yan Gao MD Yizhen Liu MD PhD Yafei Wang MD Qingyuan Zhang MD Depei Wu MD Xu Ye MD Jianqiu Wu MD Wei Xu MD Jianfeng Zhou MD Yu Yang MD Hong Cen MD Feng Zhang MD Ying Xiang MD Xiaoqiong Tang MD Kaiyang Ding MD JinYing Lin MD Lei Ma MD Shunqing Wang MD Hao Yu MD Yang Zhao MD Bin Song MD Fangfang Lv MD Huiqiang Huang MD 《Cancer》2023,129(4):551-559
4.
Shiyu Jiang Yan Qin Hongxin Jiang Biao Liu Jianming Shi Fanlu Meng Peng Liu Jianliang Yang Sheng Yang Xiaohui He Shengyu Zhou Lin Gui Hao Liu Jing Lin Han Han-Zhang Yuankai Shi 《International journal of cancer. Journal international du cancer》2020,147(9):2611-2620
Diffuse large B-cell lymphoma (DLBCL) is a clinically aggressive and heterogenous disease. Although most patients can be cured by immunochemotherapy, 30% to 40% patient will ultimately develop relapsed or refractory disease. Here, we investigated the molecular landscapes of patients with diverse responses to R-CHOP. We performed capture-based targeted sequencing on baseline samples of 105 DLBCL patients using a panel consisting of 112 lymphoma-related genes. Subsequently, 81 treatment-naïve patients with measurable disease and followed for over 1 year were included for survival analysis. Collectively, the most commonly seen mutations included IGH fusion (69%), PIM1(33%), MYD88 (29%), BCL2 (29%), TP53 (29%), CD79B (25%) and KMT2D (24%). Patients with TP53 mutations were more likely to have primary refractory disease (87.0% vs 50.0%, P = .009). For those with TP53 disruptive mutations, 91.7% patients were in the primary refractory group. Interestingly, BCL-2 somatic hypermutation was only seen in patients without primary refractory disease (P = .014). In multivariate analysis, BCL-2 amplification (hazard ratio [HR] = 2.94, P = .022), B2M mutation (HR = 2.99, P = .017) and TP53 mutation (HR = 3.19, P < .001) were independently associated with shorter time to progression (TTP). Furthermore, TP53 mutations was correlated with worse overall survival (P = .049). Next, we investigated mutation landscape in patients with wild-type (WT) TP53 (n = 58) and found that patients harboring MYD88 L265P had significantly inferior TTP than those with WT or non-265P (P = .046). Our study reveals the mutation spectrum of treatment-naive Chinese DLBCL patients. It also confirms the clinical significance of TP53 mutations and indicates the prognostic value of MYD88 L265P in TP53 WT patients. 相似文献
5.
6.
Leopold Sellner Fuli Fan Nicola Giesen Maria-Luisa Schubert Hartmut Goldschmidt Carsten Müller-Tidow Peter Dreger Marc S. Raab Michael Schmitt 《International journal of cancer. Journal international du cancer》2020,147(8):2029-2041
Despite major advances in the treatment of multiple myeloma (MM), it remains a largely incurable disease with long-term control often dependent on continuous therapy. More effective, better tolerated treatments are therefore required to achieve durable remissions and to improve the quality of life of MM patients. Adoptive immunotherapy employing T cells expressing chimeric antigen receptors (CAR) is currently among the most promising treatment approaches in cancer. Within the target portfolio for MM immunotherapy, B-cell maturation antigen (BCMA) is among the most widely studied target antigens. BCMA is consistently expressed on MM cells and, importantly, is not expressed in critical healthy tissue. For this reason, it is an ideal target for MM immunotherapy. Several clinical trials evaluating different BCMA-targeting CAR constructs have been initiated and early results are very promising. However, in this rapidly developing clinical landscape, the ultimate role of BCMA-specific CAR-T cell therapy remains unclear. In this review, we will summarize currently available clinical data on BCMA-directed CAR-T cells and discuss potential future perspective for this promising treatment approach in MM. 相似文献
7.
8.
9.
[摘要] HIV相关淋巴瘤是常见的HIV相关肿瘤之一,在联合抗反转录病毒治疗(combination antiretroviral therapy, cART)出现之前,其治疗效果极差。在cART时代,HIV相关淋巴瘤的基础及临床研究取得了重大进展,这些为挖掘治疗新靶点提供了依据,使优化HIV相关淋巴瘤的诊治成为可能。本文对近年来HIV相关淋巴瘤的诊断和治疗进展进行综述。 相似文献